Add to ORKGBased on an analysis of relevant laws and policies, regulator data portals, and information requests, we find that clinical data, including clinical study reports, submitted to the European Medicines Agency and Health Canada to support approval of medicines are routinely made publicly available
Transparency and sharing of information from clinicaltrials have developed swiftly during the past 2...
Abstract Background Clinical trial transparency is important to participants, trialists, publishers,...
The concept of transparency has gained widespread appeal in the European pharmaceutical domain, not ...
Based on an analysis of relevant laws and policies, regulator data portals, and information requests...
Over the past 10 years, European pharmaceutical regulators (especially the European Medicines Agency...
Over the past 10years, European pharmaceutical regulators (especially the European Medicines Agency ...
ABSTRACT Regulatory transparency is an imperative characteristic of a reliable National Regulatory A...
Openness and transparency are important considerations for medicines regulators, where public health...
This article reflects on the state of play as regards access to non-summary clinical trial data in t...
The Chapter outlines the relevant provisions governing access to information concerning quality, saf...
In Europe and North America, there is increasing political pressure being put on health regulatory a...
In recent years, European pharmaceutical regulators have increasingly committed to heightening acces...
In recent years, European pharmaceutical regulators have increasingly committed to heightening acces...
The European legislative framework is quickly moving towards transparency of the clinical trials dat...
Hard-won gains in the transparency of therapeutic product data in recent years1 have occurred alongs...
Transparency and sharing of information from clinicaltrials have developed swiftly during the past 2...
Abstract Background Clinical trial transparency is important to participants, trialists, publishers,...
The concept of transparency has gained widespread appeal in the European pharmaceutical domain, not ...
Based on an analysis of relevant laws and policies, regulator data portals, and information requests...
Over the past 10 years, European pharmaceutical regulators (especially the European Medicines Agency...
Over the past 10years, European pharmaceutical regulators (especially the European Medicines Agency ...
ABSTRACT Regulatory transparency is an imperative characteristic of a reliable National Regulatory A...
Openness and transparency are important considerations for medicines regulators, where public health...
This article reflects on the state of play as regards access to non-summary clinical trial data in t...
The Chapter outlines the relevant provisions governing access to information concerning quality, saf...
In Europe and North America, there is increasing political pressure being put on health regulatory a...
In recent years, European pharmaceutical regulators have increasingly committed to heightening acces...
In recent years, European pharmaceutical regulators have increasingly committed to heightening acces...
The European legislative framework is quickly moving towards transparency of the clinical trials dat...
Hard-won gains in the transparency of therapeutic product data in recent years1 have occurred alongs...
Transparency and sharing of information from clinicaltrials have developed swiftly during the past 2...
Abstract Background Clinical trial transparency is important to participants, trialists, publishers,...
The concept of transparency has gained widespread appeal in the European pharmaceutical domain, not ...